LAMIVUDINE

Post-LOE

lamivudine

Signatur Biosciences

ANDAORALTABLET

Approved

Dec 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

LAMIVUDINE (lamivudine) by Signatur Biosciences is nucleoside reverse transcriptase inhibitors [moa]. Approved for hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2014.

Drug data last refreshed 17h ago

$0.0BPart D

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT00000887Phase 1Completed

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

24 enrolled

HIV InfectionsPregnancy

NCT00014014Phase 1Completed

Zidovudine and Lamivudine Given Once Versus Twice Daily

20 enrolled

HIV Infections

NCT00001075N/ACompleted

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

55 enrolled

HIV Infections

NCT00000901Phase 1Completed

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

24 enrolled

HIV Infections

NCT00000888Phase 1Completed

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

14 enrolled

HIV InfectionsPregnancy

Worked on LAMIVUDINE at Signatur Biosciences? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.